SAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced financial results for the three months ended September 30, 2024, and provided a corporate update. "Triple drug therapies (triplets) that build on the standard of care in AML have yielded higher response rates yet are limited to ...

Core Viewpoint - Aptose Biosciences Inc. held a special meeting of shareholders on September 5, 2024, where key proposals regarding the issuance of common shares and potential adjournments were approved by the requisite number of votes [1]. Proposal Summary - Proposal No. 1: Approval of the issuance of common shares underlying certain warrants was passed with 3,969,105 votes in favor, representing 93.34% of the votes cast [3]. - Proposal No. 2: Approval for one or more adjournments of the meeting was also passed, with 97.05% of votes in favor [3]. Voting Results - A total of 6,052,460 common shares were voted, accounting for 33.42% of the issued and outstanding shares [1][3]. - The breakdown of votes for Proposal No. 1 included 3,969,105 votes for, 267,013 against, and 16,342 withheld/abstained [3]. - The total shares issued and outstanding were reported as 18,109,393, with 1,800,000 shares held by insiders excluded from the voting results [3]. Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [4]. - The lead compound, tuspetinib, is an oral kinase inhibitor targeting acute myeloid leukemia (AML) and is being developed for both monotherapy and combination therapy [4].

Core Insights - Aptose Biosciences Inc. has secured a $10 million loan from Hanmi Pharmaceutical Co. Ltd. to support the development of tuspetinib, an oral kinase inhibitor for acute myeloid leukemia (AML) [1][2] - The loan can be converted into prepayment of milestone obligations or repaid after the completion of a triple drug combination trial with tuspetinib in newly diagnosed AML patients [1] - Aptose and Hanmi are negotiating a new co-development collaboration agreement to provide additional funding for the clinical development of tuspetinib [2] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [3] - The company's lead compound, tuspetinib, has shown efficacy as both a monotherapy and in combination therapy for relapsed or refractory AML, and is being developed as a frontline triplet therapy for newly diagnosed AML [3]

SAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, today announced that its special meeting of shareholders (the "Meeting") convened on August 15, 2024, at 1:00 p.m. (ET) has been adjourned to September 5, 2024 at 1 p.m. (ET), without business being considered, due to a lack of quorum. At the t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporation or ...

EXHIBIT 99.1 Aptose Reports Results for the Second Quarter 2024 TUS+VEN+HMA Triplet Protocol in Frontline Therapy for Newly Diagnosed AML was Reviewed by the FDA and Allowed to Proceed Abstract Supporting Exploration of the TUS+VEN+AZA Triplet in Frontline Therapy for Newly Diagnosed AML has been Submitted to the 2025 Annual Meeting of the American Society of Hematology (ASH) SAN DIEGO and TORONTO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS) ...

SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company's annual and special meeting of shareholders held today, June 18, 2024 (the "Meeting"). A total of 8,101,527 common shares of the Company, representing 49.67% of the common shares of the Compa ...

SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company’s annual and special meeting of shareholders held today, June 18, 2024 (the “Meeting”). A total of 8,101,527 common shares of the Company, representing 49.67% of the common shares of the Com ...

TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in Difficult-to-treat Genetic Subgroups, FLT3 Wildtype AML TUS Shown to Target VEN Resistance Mechanisms and Retain Activity on VEN-Resistant AML Cells in Preclinical Study TUS+VEN+Azacitidine (AZA) Triplet Trial to Treat Newly D ...

TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in Difficult-to-treat Genetic Subgroups, FLT3 Wildtype AML TUS Shown to Target VEN Resistance Mechanisms and Retain Activity on VEN-Resistant AML Cells in Preclinical Study TUS+VEN+Azacitidine (AZA) Triplet Trial to Treat Newly D ...